Koen K Van Rompay

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California, USA
    Antimicrob Agents Chemother 56:4980-4. 2012
  2. pmc Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Retrovirology 9:57. 2012
  3. doi request reprint The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, 95616, USA
    AIDS Res Hum Retroviruses 28:16-35. 2012
  4. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
  5. ncbi request reprint Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis, CA 95616 8542, USA
    J Infect Dis 184:429-38. 2001
  6. pmc Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Antimicrob Agents Chemother 49:2093-4. 2005
  7. pmc 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis 95616, USA
    Antimicrob Agents Chemother 40:2586-91. 1996
  8. ncbi request reprint Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    AIDS Rev 7:67-83. 2005
  9. pmc Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California, USA
    Virol J 3:22. 2006
  10. pmc Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    J Virol 80:6399-410. 2006

Research Grants

  1. Topical virucides to prevent oral transmission
    Koen van Rompay; Fiscal Year: 2004

Collaborators

Detail Information

Publications34

  1. pmc Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California, USA
    Antimicrob Agents Chemother 56:4980-4. 2012
    ..In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels and better immune preservation...
  2. pmc Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Retrovirology 9:57. 2012
    ..We report here follow-up data on 5 such animals that received tenofovir for 8 to 14 years...
  3. doi request reprint The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, 95616, USA
    AIDS Res Hum Retroviruses 28:16-35. 2012
    ....
  4. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
    ..J. Virology 77:179-190, 2003). Here we evaluate the impact of these vaccines on oral transmission and evolution of SIV envelope variants...
  5. ncbi request reprint Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis, CA 95616 8542, USA
    J Infect Dis 184:429-38. 2001
    ..These data suggest that 1 or 2 doses of PMPA may protect human newborns against intrapartum HIV infection...
  6. pmc Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Antimicrob Agents Chemother 49:2093-4. 2005
    ..Peak concentrations and area under the curve values of tenofovir in milk were approximately 3 and approximately 20% of those detected in serum, respectively...
  7. pmc 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis 95616, USA
    Antimicrob Agents Chemother 40:2586-91. 1996
    ..Our data suggest that PMPA holds much promise for the treatment of human immunodeficiency virus-infected human infants and adults...
  8. ncbi request reprint Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    AIDS Rev 7:67-83. 2005
    ..Accordingly, well-designed drug studies in nonhuman primates can continue to provide a solid scientific basis to advance our scientific knowledge and to guide future clinical trials...
  9. pmc Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California, USA
    Virol J 3:22. 2006
    ..Thus, CD8+ cell-mediated immune responses play an important role in controlling SIVmac1A11 replication during acute viremia...
  10. pmc Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    J Virol 80:6399-410. 2006
    ....
  11. ncbi request reprint Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616 8542, USA
    J Acquir Immune Defic Syndr 43:6-14. 2006
    ..These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations...
  12. pmc Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, USA
    Retrovirology 4:25. 2007
    ..Accordingly, to model HIV-1 RT responses, 12 macaques were inoculated with RT-SHIV, a chimeric SIV containing HIV-1 RT, and started on prolonged tenofovir therapy 5 months later...
  13. pmc Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California 95616, USA
    Antimicrob Agents Chemother 52:3144-60. 2008
    ..In conclusion, these findings illustrate the safety and sustained benefits of prolonged TFV-containing regimens throughout development from infancy to adulthood, including pregnancy...
  14. doi request reprint Evaluation of antiretrovirals in animal models of HIV infection
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Antiviral Res 85:159-75. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  15. pmc 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis 95616, USA
    Antimicrob Agents Chemother 43:802-12. 1999
    ..These results suggest that the potential emergence of HIV mutants with reduced susceptibility to PMPA in patients during prolonged PMPA therapy may not eliminate its therapeutic benefits...
  16. ncbi request reprint Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis 95616, USA
    AIDS Res Hum Retroviruses 14:761-73. 1998
    ..Our data demonstrate that PMPA treatment can reduce perinatal SIV infection and suggest that similar strategies may also be effective against HIV...
  17. pmc Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
    K K Van Rompay
    California Regional Primate Research Center, University of California, Davis, California 95616, USA
    J Virol 74:1767-74. 2000
    ....
  18. ncbi request reprint Motor-biking through rural India on an HIV mission
    Koen K A Van Rompay
    University of California, Davis, USA
    AIDS 18:N13-6. 2004
  19. ncbi request reprint Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Antiviral Res 63:133-8. 2004
    ....
  20. ncbi request reprint The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters
    Koen K A Van Rompay
    The California National Primate Research Center, Davis, 95616, USA
    J Acquir Immune Defic Syndr 36:900-14. 2004
    ..Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters...
  21. pmc CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment
    Koen K A Van Rompay
    California National Primate Research Center, University of California Davis, Davis, CA 95616, USA
    J Virol 78:5324-37. 2004
    ....
  22. ncbi request reprint Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California 95616 8542, USA
    J Infect Dis 186:1508-13. 2002
    ..In a subsequent study, 2 oral inoculations of 4 juvenile macaques with a mixture of tenofovir DF and SIVmac251 induced persistent infection. Topical administration of low doses of tenofovir DF did not protect against oral SIV infection...
  23. pmc Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis, California 95616, USA
    Antimicrob Agents Chemother 48:1469-87. 2004
    ....
  24. pmc Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase
    Koen K A Van Rompay
    California Regional Primate Research Center, University of California, Davis, California 95616, USA
    J Virol 76:6083-92. 2002
    ..These data demonstrate that the M184V mutation in SIV conferred a slightly reduced fitness but did not affect disease outcome...
  25. ncbi request reprint Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV
    Koen K A Van Rompay
    California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA
    J Acquir Immune Defic Syndr 38:124-34. 2005
    ..The results of these investigations suggest that immunization of human infants with poxvirus-based HIV vaccine candidates may offer protection against early and late HIV infection through breastfeeding...
  26. pmc Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV
    Koen K A Van Rompay
    California National Primate Research Center, University of California Davis, Davis, CA 95616, United States
    Vaccine 28:1481-92. 2010
    ....
  27. pmc Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis 95616, USA
    J Virol 77:179-90. 2003
    ....
  28. pmc Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine
    Jeffrey P Murry
    Center for Comparative Medicine, University of California, Davis 95616, USA
    J Virol 77:1120-30. 2003
    ..All animals receiving this combination developed the K65R mutation. These results demonstrate that the combination of PMPA with 3TC or (-)-FTC selects for the K65R mutation and against the M184V mutation in SIV RT...
  29. pmc Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1
    Thomas W North
    Center for Comparative Medicine, University of California, Davis, CA 95616, USA
    J Virol 79:7349-54. 2005
    ..These results mimic HAART of HIV-1-infected humans. The RT-SHIV/rhesus macaque model should be useful for studies of tissue reservoirs and sites of residual replication that are not possible or practical with humans...
  30. pmc Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses
    Kristina Abel
    CNPRC CCM, School of Medicine, Division of Infectious Diseases, University of California at Davis, One Shields Ave, Davis, CA 95616, USA
    J Virol 80:6357-67. 2006
    ....
  31. pmc Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques
    Magdalena Magierowska
    Department of Medicine, University of California San Francisco, California 94118, USA
    J Virol 78:2434-44. 2004
    ....
  32. ncbi request reprint Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge
    Ruth H Florese
    Vaccine Branch, National Cancer Institute, Bethesda, MD 20892 5065, USA
    J Immunol 177:4028-36. 2006
    ..Future studies should explore additional challenge routes in juvenile macaques using higher amounts of potent IgG preparations...
  33. ncbi request reprint Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques
    Agneta S von Gegerfelt
    Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    AIDS Res Hum Retroviruses 22:516-28. 2006
    ..This study demonstrates a potent, long-lasting control of the Rev-independent attenuated SIV in macaques independent of the age at virus exposure...
  34. ncbi request reprint Number of CD4+ and CD8+ T-cell CDR3 clonotypes expanding during acute infection of macaques with simian immunodeficiency virus
    Flavien Bernardin
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Virology 322:105-17. 2004
    ..The lack of correlation between the number of expanding T-cell clonotypes and viremia levels may reflect the highly variable selection pressure imposed on SIV by T-cell responses targeting different epitopes in outbred macaques...

Research Grants1

  1. Topical virucides to prevent oral transmission
    Koen van Rompay; Fiscal Year: 2004
    ..If topical tenofovir administration were effective, then this simple strategy would be highly affordable for developing countries. ..